NAMPT activity plays a key role in driving autoimmune processes that mediate beta-cell death and type 1 diabetes development in mice
Daniel Egbase, Sophie R. Sayers, Naila Haq, Vesela S. Gesheva, Jithu J. Varghese, Sreya Bhattacharya, Jay Kynaston, Ella L. Hubber, Lorna I. F. Smith, Timothy J. Pullen, Henry Gerdes, Vivian K. Lee, David Hopkins, Min Zhao, Yee Cheah, Joshua Greally, Sam Butterworth, James A. Pearson, Gavin A. Bewic · 2026
Read NAMPT activity plays a key role in driving autoimmune processes that mediate beta-cell death and type 1 diabetes development in mice by Daniel Egbase, Sophie R. Sayers, Naila Haq, Vesela S. Gesheva, Jithu J. Varghese, Sreya Bhattacharya, Jay Kynaston, Ella L. Hubber, Lorna I. F. Smith, Timothy J. Pullen, Henry Gerdes, Vivian K. Lee, David Hopkins, Min Zhao, Yee Cheah, Joshua Greally, Sam Butterworth, James A. Pearson, Gavin A. Bewic (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13470499.txt.
Description
Egbase and a large team showed in 2026 that blocking an enzyme called NAMPT shields insulin-making beta cells from autoimmune attack. The enzyme raises levels of NAD, a core metabolic molecule, and the team suspected excess NAD fuels islet inflammation killing beta cells. They tested a blocker on mouse and human islets bathed in inflammatory signals, and a mouse diabetes model received it for 16 days.
Protection was broad: in isolated islets, the blocker preserved insulin release and prevented cell death under cytokine attack. Gene profiling showed it silenced inflammatory and cell-recruitment programs, and in diabetic mice treatment improved blood sugar control and beta-cell survival. Immune invaders inside islets thinned out, and killer T cells lost their ability to migrate into islets in dish tests. The authors float NAMPT blocking as a therapy candidate, and caution that NAD-boosting supplements deserve scrutiny in people at risk of this disease.
Catalog record
| CREATOR | Daniel Egbase, Sophie R. Sayers, Naila Haq, Vesela S. Gesheva, Jithu J. Varghese, Sreya Bhattacharya, Jay Kynaston, Ella L. Hubber, Lorna I. F. Smith, Timothy J. Pullen, Henry Gerdes, Vivian K. Lee, David Hopkins, Min Zhao, Yee Cheah, Joshua Greally, Sam Butterworth, James A. Pearson, Gavin A. Bewic |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |